Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › primary peritoneal carcinoma

Primary peritoneal carcinoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for primary peritoneal carcinoma

23 trials tracked for primary peritoneal carcinoma: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 295 citations.

23Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 19 Phase 1 2
  1. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 295 cited
  2. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 194 cited
  3. Phase 2 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Completed
  4. Phase 2 Study of Ramucirumab in Ovarian Cancer Completed
  5. Phase 2 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed
  6. Phase 2 Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer Completed
Show 17 more trials
  1. Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  2. Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed
  3. Phase 2 Irinotecan and Bevacizumab for Recurrent Ovarian Cancer Completed
  4. Phase 2 Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer Completed
  5. Phase 2 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  6. Phase 2 Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Completed
  7. Phase 2 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Completed
  8. Phase 2 EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  9. Phase 2 Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors Completed
  10. Phase 2 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma Completed
  11. Phase 2 Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Completed
  12. Phase 2 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Completed
  13. Phase 2 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma Completed
  14. Phase 2 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed
  15. Phase 2 Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Completed
  16. Phase 1 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers Completed
  17. Phase 1 Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Primary peritoneal carcinoma: what the trials found

Mirvetuximab soravtansine demonstrated an Objective Response Rate (ORR) of 22% as assessed by BIRC Per RECIST1.1, with a GCIG CA-125 response rate of 51% 1.

Bevacizumab has been evaluated in multiple trials, showing a best overall response at six months of 50% 20 and demonstrating no statistically significant difference in progression-free survival between optimal (RO) >= 1cm and suboptimal > 1 cm groups (p=0.33) 6.

Paclitaxel was evaluated in a large cohort where various counts of Grade 3 and above adverse events were recorded across different study arms 2.

Recent results — preliminary, needs further review

  • Pegylated Liposomal Doxorubicin + SL-172154 (N=86) is currently under investigation 22.

For the clinician treating this condition

  • Mirvetuximab soravtansine shows a 22% ORR and a 51% CA-125 response rate in patients with primary peritoneal carcinoma 1.
  • Bevacizumab is established as an intervention, showing a 50% best overall response at six months 20.
  • The impact of optimal vs. suboptimal surgical debulking on progression-free survival when using Bevacizumab did not reach statistical significance (p=0.33) 6.

AI synthesis of 5 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
Oncology RCT
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Apr 23, 2026

Research across Cancer

Related studies from across the Cancer family.

Review of a case report on epithelioid clear cell mesothelioma in a 76-year-old male with 24 months follow-up
Oncology Sys. Review
Review of a case report on epithelioid clear cell mesothelioma in a 76-year-old male with 24 months follow-up A 76-year-old man with rare cancer stayed cancer-free for two years
This publication is a review of a single case report involving a 76-year-old male with epithelioid clear cell mesothelioma. The patient had …
A 76-year-old man with a rare form of cancer had no signs of the disease returning after two years, offering hope for others facing this dif…
Frontiers May 18, 2026
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Oncology RCT
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Apr 28, 2026